India posts draft guidance on stability data for clinical trials

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial Pharmacology

India posts draft guidance on stability data for clinical trials
India has released draft guidance on stability data needed to support approval of Phase I to III clinical trials.

Like its US counterpart India’s Central Drugs Standard Control Organization (CDSCO) proposes unique stability data requirements for each phase of clinical development. Outlining these demands in draft guidance is intended to help biopharm companies support their applications with suitable data.

This guidance will ensure that sufficient data is submitted to CDSCO to assess the safety as well [as] the quality of the proposed clinical trials from chemical and pharmaceutical information perspective​”, the regulator wrote. The guidance does not apply to biologics and vaccines.

For Phase I trials CDSCO, like the US Food and Drug Administration (FDA)​, has minimal requirements. However, the approach is different, with CDSCO asking applicants to “submit whatever stability study data [is] available​” and the FDA calling for samples to be tested for the duration of the Phase I trial.

As a compound advances through drug development CDSCO’s stability data requirements increase. In Phase II a minimum of one month accelerated and real-time stability study data is needed. CDSCO also asks for quarterly updates on stability and to be told of significant changes within 10 days.

The FDA guidance differs​ by making no mention of specific Phase II requirements, such as the one month of stability data. Also, the FDA asks firms to “consider the development of stability-indicating analytical procedures that will detect significant changes in the quality of the drug product​”.

CDSCO Phase III needs are identical to its Phase II draft. In contrast, the FDA adds data requirements in Phase III, asking for one-time stress tests of certain products and development of a protocol for use in formal stability studies. This ensures data for the NDA (new drug application) is generated.

Comments can be sent to CDSCO until January 20.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more